Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASH

News
Video

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed the benefits of treating patients with newer agents, such as the Bruton tyrosine kinase inhibitor ibrutinib [Imbruvica], over chemoimmunotherapy. During the meeting, she is presenting data on ibrutinib-containing regimens in patients 65 years or older, which has been shown to be superior to treatment with bendamustine plus rituximab.

Transcript:

I hope that this continues to make practitioners choose novel therapies for their patients over chemoimmunotherapy. I think there are some special situations where chemoimmunotherapy is still appropriate, but for most patients, they will do better with Bruton’s tyrosine kinase [BTK] inhibitors or with venetoclax [Venclexta] plus obintuzumab [Gazyva] as opposed to a chemoimmunotherapy regimen. The other big thing that we’ve seen from [the phase 3 AO41202 (NCT01886872) trial], and has been shown from other trials in the frontline setting, is that TP53 abnormalities especially don’t make a difference in outcomes with ibrutinib at this time point at least. Patients with or without 17p deletion, with or without TP53 mutation will likely derive the same benefit from ibrutinib. This does set this drug apart from some other classes of medications, even among the novel agents.

Reference

Woyach JA, Ruppert AS, Heerema NA, et al. Long-term results of Alliance AO41202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA. Accessed December 6, 2021. https://bit.ly/31EcBlO

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content